RE:RE:RE:RE:RE:RE:Forcing Bioasis to AnswerSo, poof, have you considered the possibility that there are two or more xB3 deals that could be done with Ellipses?
xB3-001 is one, obviously. That one deals with HER2+ but not other HER2 (triple neg, for instance) types of breast cancer and metastases.
The Ellipses/SunRock drug, EP0017, is also a likely candidate for transport across the BBB. It's a fusion protein targeting HER3 (and DR$ and DR%), and it's too big to get itself across the BBB in therapeutic quantities.
Your may be making the case for even more Bioasis business with Ellipses, not less business.
jd